Drawing for STELTRIS

USPTO serial 86498159

STELTRIS

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
HISER, CHARLES
Law office
TMO LAW OFFICE 112 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with STELTRIS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Diane Fry Maginnis

DIANE FRY MAGINNIS GlaxoSmithKlineFive Moore DriveLegal Global Trademarks, Mailstop: 5.5AResearch Triangle Park, NC 27709-0183

Goods and services

ClassDescriptionStatusFirst use
005(Based on Intent to Use) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(d) Priority Application) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; VaccinesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Jun 3, 2016MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 3, 2016ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 3, 2016DOCKASSIGNED TO EXAMINER—
Nov 2, 2015GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Nov 2, 2015GNSIINQUIRY TO SUSPENSION E-MAILED—
Nov 2, 2015CNSISUSPENSION INQUIRY WRITTEN—
Oct 19, 2015RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Oct 7, 2015ALIEASSIGNED TO LIE—
Jun 23, 2015TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 24, 2015GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Mar 24, 2015GNSLLETTER OF SUSPENSION E-MAILED—
Mar 24, 2015CNSLSUSPENSION LETTER WRITTEN—
Mar 24, 2015DOCKASSIGNED TO EXAMINER—
Jan 20, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 12, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance